
Halliburton stock has nearly doubled over the past five years, and the current valuation checks still lean on the cheap side for a business that has already delivered strong medium term gains. A roughly 96.9% return over five years suggests Halliburton has already rewarded patient holders, so the question is how much of the story is now reflected in the price. The recently awarded bp contract for the Bumerangue field in Brazil can support investor confidence in Halliburton's technology led...






